Quốc gia: Vương quốc Anh
Ngôn ngữ: Tiếng Anh
Nguồn: MHRA (Medicines & Healthcare Products Regulatory Agency)
Pindolol
Advanz Pharma
C07AA03
Pindolol
15mg
Oral tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02040000; GTIN: 5060064170465
1. NAME OF THE MEDICINAL PRODUCT Visken 15 mg_ _Tablets Pindolol 15mg Tablets 2. QUALITATIVE AND QUANTITATIVE COMPOSITION Each tablet contains 15 mg pindolol. For the full list of excipients, see section 6.1. 3. PHARMACEUTICAL FORM Tablet. White, round, flat, bevelled tablets, marked ‘Visken 15’ on one side and with a score line on the other. The score line is only to facilitate breaking for ease of swallowing and not to divide into equal doses. 4. CLINICAL PARTICULARS 4.1 THERAPEUTIC INDICATIONS _ _ This medicine is indicated in adults for the treatment of essential hypertension. It is also used as a prophylactic treatment of angina pectoris. 4.2 POSOLOGY AND METHOD OF ADMINISTRATION POSOLOGY _ _ Adults _Essential Hypertension: _Initially one 5 mg tablet two or three times a day. According to the response of the patient the dose may be increased at weekly intervals to a maximum of 45 mg given in divided doses twice or three times daily. _ _ _Once daily dosage schedule: _Further work shows that many patients respond to a once daily dosage regime. Initially 15 mg (3 tablets) should be taken once a day with breakfast and adjusted according to individual response up to a maximum of 45 mg (9 tablets). Most patients respond to a once daily dose of between 15-30 mg (3-6 tablets). The onset of action of this medicine is usually rapid, with most patients showing a response within the first one to two weeks of treatment. However, the maximum response may take several weeks to develop. _ _ _Prophylactic treatment of Angina pectoris: _Usually 2.5 mg to 5 mg orally three times a day according to response. It reduces the frequency and severity of anginal attacks and increases work capacity. Paediatric population The safety and efficacy of this medicine in children has not been established. Its use is therefore not recommended. Use in the elderly No evidence exists that elderly patients require different dosages or show different side-effects from younger patients. Route of administration Oral. 4.3 CONTRAINDICATIONS This m Đọc toàn bộ tài liệu